A 78-Year-Old Man With Metastatic Melanoma and a 67-Year-Old Woman With Stage IV Melanoma : Episode 5

The Role of Lymphocyte-Activation Gene 3 (LAG-3) in Metastatic Melanoma

November 1, 2023

Opinion

Video

Hussein Tawbi, MD, PhD, explains that LAG-3 is a marker of T-cell exhaustion, and combining LAG-3 inhibitors with PD-1 inhibitors can reverse this exhaustion, enhancing T-cell effectiveness and showing therapeutic benefits in patients with metastatic melanoma.

EP: 1.Case Presentation: A 78-Year-Old Man With Metastatic Melanoma

EP: 2.Common Clinical Presentations of Metastatic Melanoma

EP: 3.Significance of Biomarker and Genetic Testing in Diagnosing Metastatic Melanoma

EP: 4.Available First-Line Systemic Therapy Options for Patients With Metastatic Melanoma

Now Viewing

EP: 5.The Role of Lymphocyte-Activation Gene 3 (LAG-3) in Metastatic Melanoma

EP: 6.Relatlimab/Nivolumab in Metastatic Melanoma: Data From the RELATIVITY-047 Trial

EP: 7.IO Monotherapy Versus Combination Dual IO Therapy for the First-Line Treatment of Metastatic Melanoma

EP: 8.Key Trial Data in the Frontline Treatment of Metastatic Melanoma

EP: 9.Managing Adverse Events in Patients With Metastatic Melanoma Receiving First-Line Systemic Therapy

EP: 10.Case Presentation: A 67-Year-Old Woman With Stage IV Melanoma

EP: 11.Available First-Line Systemic Therapy Options for Patients With Metastatic Melanoma with a BRAF Mutation

EP: 12.Nivolumab/Ipilimumab Followed by Dabrafenib/Trametinib in Metastatic Melanoma: Data From the DREAMseq Trial

EP: 13.Second-Line Treatment Options for Patients With Metastatic or Unresectable Melanoma After Disease Progression

EP: 14.Clinical Pearls on the Treatment of Metastatic and Unresectable Melanoma

Related Content

VMT01 Earns FDA Fast Track Designation in MC1R-Positive Melanoma

Sabrina Serani

September 9th 2024

Article

The novel agent VMT01 is designed to target and deliver 212Pb to MC1R-expressing tumors like metastatic melanoma.

Advancing Melanoma Treatment: Hamid on Lifileucel's Role

Jordyn Sava;Omid Hamid, MD

July 15th 2024

Podcast

In this episode of Targeted Talks, Omid Hamid, MD, discusses data supporting the use of lifileucel for the treatment of advanced melanoma.

Listen

FDA Grants RMAT Designation to Novel TIL Therapy OBX-115 in Melanoma

Sabrina Serani

September 3rd 2024

Article

This designation follows the fast track designation that was granted to OBX-115 for the same indication in July 2024.

Understanding and Treating Mucosal Melanoma

Nichole Tucker;Richard Carvajal, MD

April 14th 2023

Podcast

In season 4, episode 4 of Targeted Talks, Richard D. Carvajal, MD, discusses mucosal melanoma and treatment options for the disease.

Listen

Similar Efficacy in Melanoma Shown in Indirect Comparison of PD-1/LAG3 vs PD-1/CTLA-4

Targeted Oncology Staff

July 16th 2024

Article

During a Case-Based Roundtable® event, Michael A. Postow, MD, discussed an indirect treatment comparison of nivolumab plus relatlimab vs nivolumab plus ipilimumab in patients with advanced melanoma in the second article of a 2-part series.